TABLE 2.
Assay | Company | Type | Antigen | Platform | Testing site(s) |
---|---|---|---|---|---|
Platelia SARS-CoV-2 total Ab | Bio-Rad, Clinical Diagnostics, Montréal, Quebec, Canada | ELISA | Nucleocapsid | Evolis | 1 and 2 |
SARS-CoV-2 IgG | Abbott Diagnostics, Missisauga, Ontario, Canada | CMIA | Nucleocapsid | Architect i2000SR | 1 and 2 |
Elecsys anti-SARS-CoV-2 | Roche Diagnostics, Laval, Quebec, Canada | ECLIA | Nucleocapsid | Cobas e411 and e602 | 1 and 2 |
VITROS Immunodiagnostic Products anti-SARS-CoV-2 total Ab, anti-SARS-CoV-2 IgG | Ortho-Clinical Diagnostic, Ottawa, Ontario, Canada | CLIA | Spike | Vitros 5600 | 2 and 4 |
Anti-SARS-CoV-2 ELISA (IgA), anti-SARS-CoV-2 ELISA (IgG) | EuroImmun, Missisauga, Ontario, Canada | ELISA | Spike domain 1 | EuroImmun Analyser I | 3 and 4 |
Liaison SARS-CoV-2 S1/S2 IgG | DiaSorin Canada, Missisauga, Ontario, Canada | CLIA | Spike domains 1 and 2 | Liaison XL | 1 and 5 |
SARS-CoV-2 IgG | Beckman Coulter, Missisauga, Ontario, Canada | CLIA | Spike RBD | Unicell Dxl 800 | 1 and 2 |
SARS-CoV-2 total Ab | Siemens, Missisauga, Ontario, Canada | CLIA | Spike RBD | Advia Centaur XPT | 2 and 3 |
Rapid Response COVID-19 IgG/IgM test cassette | BTNX, Markham, Ontario, Canada | LFCIA | SARS-CoV-2 antigens | NA | 6 |
Tell Me Fast novel coronavirus (COVID-19) IgG/IgM antibody test | Biocan, Coquitlam, British Colombia, Canada | LFCIA | recCOVID-19 antigen | NA | 6 |
NADAL COVID-19 IgG/IgM test | Luminarie Canada, Montréal, Quebec, Canada | LFCIA | SARS-CoV-2 antigens | NA | 6 |
ELISA, enzyme-linked immunosorbent assay; CMIA, chemiluminescent microparticle immunoassay; CLIA, chemiluminescent immunoassay; ECLIA, electrochemiluminescent immunoassay; LFCIA, lateral flow chromatographic immunoassay; rec, recombinant; NA, not applicable.